Genentech pulls breast cancer drug after FDA questions accelerated approval
August 30, 2021 at 17:48 PM EDT
The $8,000-a-month drug is still available for other types of cancer, but was voluntarily withdrawn by Genentech for metastatic triple-negative breast cancer.
